New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 12, 2012
14:19 EDTIPXLFDA delay of Impax's Rytary should have little impact on outlook, says Needham
After the FDA extended the PDUFA for Impax's Rytary by three months but didn't request any new clinical trials, Needham expects the move to little impact on the outlook of investors, who had expected the drug to be approved with little difficulty. The firm expects the drug to be approved but believes that peak sales will be below the company's guidance. Needham maintains a Hold rating on the shares.
News For IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 8, 2014
11:30 EDTIPXLLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
07:29 EDTIPXLUBS to hold investor trip
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use